Krsnaa Diagnostics Ltd

Krsnaa Diagnostics announced that the Board of Directors of the Company at its meeting held on 12 May 2025, inter alia, have recommended the final dividend of Rs 2.75 per equity Share (i.e. 55%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Net profit of Krsnaa Diagnostics rose 10.41% to Rs 20.68 crore in the quarter ended March 2025 as against Rs 18.73 crore during the previous quarter ended March 2024. Sales rose 11.91% to Rs 186.08 crore in the quarter ended March 2025 as against Rs 166.28 crore during the previous quarter ended March 2024. For the full year,net profit rose 36.54% to Rs 77.61 crore in the year ended March 2025 as against Rs 56.84 crore during the previous year ended March 2024. Sales rose 15.74% to Rs 717.16 crore in the year ended March 2025 as against Rs 619.63 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales186.08166.28 12 717.16619.63 16 OPM %28.4726.28 -26.5123.28 - PBDT50.5640.72 24 191.01144.55 32 PBT28.6122.61 27 102.6970.01 47 NP20.6818.73 10 77.6156.84 37 Powered by Capital Market - Live

Krsnaa Diagnostics will hold a meeting of the Board of Directors of the Company on 12 May 2025.Powered by Capital Market - Live

 Krsnaa Diagnostics announced that ICRA has reaffirmed a long-term rating of ICRA A (Stable) (pronounced ICRA A) for Rs 111.88 crore and a short-term rating of ICRA A1 (pronounced ICRA A One) for Rs 112.00 crore Bank Loan Facilities. The Outlook on the long-term rating is Stable.Powered by Capital Market - Live

Net profit of Krsnaa Diagnostics rose 49.73% to Rs 19.42 crore in the quarter ended December 2024 as against Rs 12.97 crore during the previous quarter ended December 2023. Sales rose 10.23% to Rs 174.51 crore in the quarter ended December 2024 as against Rs 158.32 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales174.51158.32 10 OPM %25.8323.62 - PBDT48.1837.33 29 PBT25.4816.10 58 NP19.4212.97 50 Powered by Capital Market - Live

Krsnaa Diagnostics will hold a meeting of the Board of Directors of the Company on 12 February 2025.Powered by Capital Market - Live

Revenue from operations jumped by 19.87% year-on-year (YoY) to Rs 186.34 crore in the quarter ended 30 September 2024. During the quarter, EBITDA was at Rs 49.4 crore, up 55.34% YoY. EBITDA margin improved to 26% in Q2 FY25, compared to 21% reported in the same quarter of the previous year. Profit before tax in Q2 FY25 stood at Rs 25.40 crore, up by 89.41% from Rs 13.41 crore in Q2 FY24. On half year basis the company's consolidated net profit surged 49.23% to Rs 375.17 crore in H1 FY25 as against Rs 251.39 crore posted in H1 FY24. The company's revenue from operation jumped 20.86% YoY to Rs 356.57 crore in H1 FY25. Yash Mutha, joint managing director, said, 'We are pleased to report another strong quarter, with significant margin improvements highlighting the success of our operational efficiency initiatives. Additionally, we are excited to introduce new strategic initiatives aimed at expanding our footprint and enhancing service delivery. A key highlight is our entry into Jharkhand, marking a significant milestone in our mission to bring quality diagnostic services to underserved regions. This expansion is part of our broader commitment to providing accessible, affordable, and accurate diagnostics to both urban and rural populations across the country. Our recently announced partnership with Apulki and United Imaging positions us to accelerate growth, expand our market presence, and introducing cutting edge technologies and create new value for our shareholders. We remain focused on executing our long-term strategy of delivering sustainable, profitable growth by leveraging core strengths, optimizing cost structures, and investing in high-growth opportunities. Our senior management remains deeply committed to executing our core growth strategies and we are confident in our ability to meet our annual revenue and profitability targets. The future holds immense potential and we are actively participating in more tenders while building a strong pipeline for continued growth and success.' Pallavi Bhatevara, Executive Director, said, 'In a landmark initiative poised to transform the diagnostics landscape in India, Krsnaa Diagnostics has entered into a strategic partnership with Medikabazaar, India's leading B2B healthcare procurement and supply chain solutions provider, and United Imaging, a global leader in advanced imaging technologies. This collaboration aims to disrupt the industry by introducing cutting-edge radiology equipment to our centers, enabling us to offer superior diagnostic imaging services. Our strategic investment in Apulki Healthcare further expands Krsnaa's opportunities in the fields of oncology and cardiology, allowing us to provide a comprehensive range of services in both radiology and pathology. Currently, Krsnaa Diagnostics is well-positioned to deploy 21 CT scan units, 24 MRI machines, establish 1 lab, and set up 731 collection centers, all under various contractual agreements. These recent contract wins highlight the exceptional capabilities of our in-house teams, showcasing their proficiency in navigating the complex bidding process, meeting all requirements, and successfully securing these contracts. As we embark on these projects, Krsnaa Diagnostics is actively expanding its footprint into new geographical regions, laying a strong foundation for sustainable, long-term growth.' Krsnaa Diagnostics is a differentiated diagnostic service provider in India. It provides a range of technology-enabled diagnostic services such as imaging (including radiology), pathology/clinical laboratory and tele-radiology services to public and private hospitals, medical colleges and community health centres across India. Powered by Capital Market - Live

Net profit of Krsnaa Diagnostics rose 86.67% to Rs 19.60 crore in the quarter ended September 2024 as against Rs 10.50 crore during the previous quarter ended September 2023. Sales rose 19.87% to Rs 186.34 crore in the quarter ended September 2024 as against Rs 155.45 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales186.34155.45 20 OPM %26.5120.45 - PBDT47.6132.88 45 PBT25.4013.42 89 NP19.6010.50 87 Powered by Capital Market - Live

Krsnaa Diagnostics will hold a meeting of the Board of Directors of the Company on 25 October 2024.Powered by Capital Market - Live

Krsnaa Diagnostics has received a Letter of Intent from Medical Superintendent, Sadar Hospital, Ranchi, Jharkhand for commission, install, operate and maintain the radiology services on public private partnership basis at Sadar Hospital, Purulia Road, Ranchi 834001. Powered by Capital Market - Live